 |
 |
 |
 |
 |
 |
 |
|
|
ABIOMED Home > News > ABIOMED APPOINTS EUROPEAN GENERAL MANAGER |
||||||||||||
 |
||||||||||||||
| ABIOMED APPOINTS EUROPEAN GENERAL MANAGER | ||||||||||||||
| DANVERS,
Mass. (September 09, 2004) – ABIOMED, Inc. (NASDAQ:
ABMD) today announced the appointment of Frank Menzler as General
Manager for ABIOMED, B.V., the Company's European division. Mr. Menzler
was most recently Marketing Manager for Cardiac Surgery for Guidant
Europe, and was a co-founder of Impella Cardiotechnik AG, a developer
of minimally invasive blood pumps for use in coronary surgery and
cardiology.
"We are delighted to have Frank Menzler on board and are impressed by his European relationships, technical background and business leadership," said Michael R. Minogue, CEO and President of ABIOMED. "We believe he will contribute substantially to our mission and help increase our global presence." As General Manager, Mr. Menzler will be responsible for all business issues in Europe, Middle East and Africa. He comes to ABIOMED with more than a decade of experience in the areas of sales, marketing, business development, research and development, and investor relations for medical device and life science companies. During his tenure at Guidant, he increased revenue substantially and restructured the Cardiac Surgery EMEAC Organization (Europe, Middle East, Africa, and Canada). Prior, he co-founded and worked for four years at Impella Cardiotechnik AG, where he managed strategic business planning, helped building the initial organization and coordinated the financing rounds, helping to raise more than $30 million in grants and venture capital. While at Impella, he became a member of the delegation of the NRW State Minister of Economic Affairs. Mr. Menzler earned his Engineering Masters Degree from RWTH Aachen (University of Technology) in Aachen, Germany and his MBA from the Kellogg School of Management at Northwestern University in Evanston, USA. He also serves on the Advisory Board for HepaLife Technologies Inc, a development stage biotechnology company focused on the treatment of liver dysfunction and disease. Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company’s AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. ### Media Contact:
|
||||||||||||||
